NASDAQ: BIVI
Biovie Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their BIVI stock forecasts and price targets.

Forecast return on equity

Is BIVI forecast to generate an efficient return?

Company
N/A
Industry
140.91%
Market
90.47%

Forecast return on assets

Is BIVI forecast to generate an efficient return on assets?

Company
N/A
Industry
32.45%

BIVI earnings per share forecast

What is BIVI's earnings per share in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$1.14
Avg 2 year Forecast
-$1.51

BIVI revenue forecast

What is BIVI's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$126.8M

BIVI vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BIVI$1.14N/AN/A
SLGL$7.52N/AN/A
BLRX$4.69$19.00+305.12%Strong Buy
IMNN$1.43$15.50+983.92%Strong Buy
LSTA$2.50N/AN/A

Biovie Stock Forecast FAQ

What is BIVI's earnings growth forecast for 2025-2026?

(NASDAQ: BIVI) Biovie's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Biovie's earnings in 2025 is -$19,363,238.On average, 1 Wall Street analyst forecast BIVI's earnings for 2025 to be -$21,161,109, with the lowest BIVI earnings forecast at -$21,161,109, and the highest BIVI earnings forecast at -$21,161,109.

In 2026, BIVI is forecast to generate -$28,029,188 in earnings, with the lowest earnings forecast at -$28,029,188 and the highest earnings forecast at -$28,029,188.

If you're new to stock investing, here's how to buy Biovie stock.

What is BIVI's revenue growth forecast for 2031-2031?

(NASDAQ: BIVI) Biovie's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.

Biovie's revenue in 2025 is $0.

In 2031, BIVI is forecast to generate $2,353,709,277 in revenue, with the lowest revenue forecast at $2,353,709,277 and the highest revenue forecast at $2,353,709,277.

What is BIVI's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: BIVI) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 32.45%.

What is BIVI's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: BIVI) Biovie's current Earnings Per Share (EPS) is -$1.61. On average, analysts forecast that BIVI's EPS will be -$1.14 for 2025, with the lowest EPS forecast at -$1.14, and the highest EPS forecast at -$1.14. In 2026, BIVI's EPS is forecast to hit -$1.51 (min: -$1.51, max: -$1.51).

What is BIVI's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: BIVI) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.